Hledat výzkumný projekt
118 Výsledků
Ukončené výzkumné projekty = 
Financováno členem konsorcia IRDiRC = 
Člen ERN = 
Výzkumné projekty
BELGIE
HAINAUT
GOSSELIES
Enroll-HD: une étude de registre prospective dans une cohorte mondiale de la maladie de Huntington - BE
Institut de Pathologie et de Génétique
Département de Génétique Clinique - Institut de Pathologie et de Génétique (IPG)
BELGIE
VLAAMS BRABANT
LEUVEN
Longitudinale meting van synaptische densiteit om progressie van ziekte van Huntington te kwantificeren
UZ Leuven - Campus Gasthuisberg
Huntington Clinic
BELGIE
VLAAMS BRABANT
LEUVEN
Directe kwantitatieve vergelijking tussen [11C]UCB-J en [18F]SynVest-1 PET als markers voor synaptische dichtheid bij premanifeste en manifeste ziekte van Huntington
UZ Leuven - Campus Gasthuisberg
Huntington Clinic
KANADA
Alberta
EDMONTON
Therapeutic role of ganglioside GM1 in Huntington's disease
University of Alberta
Department of Pharmacology
KANADA
Colombie-Britannique
VANCOUVER
Novel approaches to modulate key targets in the pathogenesis of Huntington Disease
Centre for Molecular Medicine and Therapeutics
KANADA
Colombie-Britannique
VANCOUVER
Altered balance of synaptic/extrasynaptic NMDA receptor signaling in Huntington disease
University of British Columbia
Centre for Huntington Disease- UBC Hospital
KANADA
Ontario
HAMILTON
Elucidating the Protective Mechanism of Phospho-N17 Huntingtin in Huntington's disease
McMaster University
Biochemistry and Biomedical Sciences
KANADA
Ontario
HAMILTON
Defective DNA Damage Repair and Aberrant PARylation as a Mechanism of Mutant Huntingtin in Huntington's Disease
McMaster University
Biochemistry and Biomedical Sciences
KANADA
Ontario
TORONTO
DNA repair proteins as modifiers of CAG repeat instability in Huntington's disease
The Hospital for Sick Children
Genetics and Genome Biology
KANADA
Québec
QUÉBEC
Prévenir la propagation pathologiques des protéines dans la maladie de Huntington : pertinence pour la pathologie et le traitement
CHUQ - (CHUL) Centre hospitalier de l'Université Laval
Axe Neuosciences, CHUL
ČESKÁ REPUBLIKA
Capital City Prague
PRAHA 2
Markery mitochondrialni dysfunkce v presymptomatickych a casnych stadiich Huntigtonovy nemoci
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
Neurologicka klinika
FRANCIE
AUVERGNE-RHONE-ALPES
LA TRONCHE
Transport axonal et maturation neuronale: conséquences pour la fonction synaptique et les connexions neuronales en situation normale et dans la maladie de Huntington
Grenoble-Institut des Neurosciences (GIN)
Grenoble-Institut des Neurosciences
FRANCIE
AUVERGNE-RHONE-ALPES
SAINT-MARTIN-D'HÈRES
FUELING-TRANSPORT: Démêler le rôle de la protéine huntingtine dans la santé et dans la maladie de Huntington
Université Grenoble Alpes
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Rôle neuroprotecteur du CYP46A1 dans la maladie de Huntington par thérapie de transfert de gènes dans le cerveau
Institution: Information not provided - FR
FRANCIE
HAUTS-DE-FRANCE
VILLENEUVE D'ASCQ
Dyadic dynamics of couples in Huntington disease
Université Lille 3
Equipe Dynamique Emotionnelle et Pathologies
FRANCIE
ILE-DE-FRANCE
FONTENAY-AUX-ROSES
Imagerie Innovante et BIOmarqueurs cognitifs pour prédire la progression de la maladie de Huntington
CEA - Commissariat à l'Energie Atomique
Laboratoire des Maladies Neurodégénératives
FRANCIE
ILE-DE-FRANCE
PARIS
Régulations efficaces des gènes et des stérols par transfert de gènes pour la protection du striatum dans la maladie de Huntington
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière
FRANCIE
ILE-DE-FRANCE
PARIS
Recherche de stratégies thérapeutiques pour les maladies dégénératives humaines
Centre Paul Broca
Biologie et pathologie du neurone
FRANCIE
ILE-DE-FRANCE
PARIS
Cell-Type-Specific Gene and Sterol Profiling following CYP46A1 gene therapy in Huntington disease
Université Pierre et Marie Curie - Paris 6 - UPMC
Neuroscience Paris Seine (CNRS UMR8246/Inserm U1130/UMPC UMCR18)
FRANCIE
ILE-DE-FRANCE
PARIS
Réponse du cerveau à la maladie de Huntington: rôle des petites vésicules extracellulaires
Université Pierre et Marie Curie - Paris 6 - UPMC
Adaptation Biologique et Vieillissement
FRANCIE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
REPETOMICS: Instabilité génomique des répétitions étendues en HD et ALS / FTD - FR
Institut de Neurosciences de la Timone
UMR7289
NĚMECKO
Baden-Württemberg
ULM
REPETOMICS: Genomische Instabilität von erweiterten DNA-Wiederholungen bei Chorea Huntington, Amyotropher Lateralsklerose und Frontotemporaler Demenz
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
NĚMECKO
Bayern
NEUHERBERG
PolyQure: Ursächliche Behandlung von Polyglutamin-Erkrankungen durch Inhibition von TRMT2A - Hochdurchsatz- und strukturbiologische Verfahren
Helmholtz Zentrum München
Institut für Strukturbiologie - AG Niessing
NĚMECKO
Nordrhein-Westfalen
BOCHUM
TreatPolyQ: Allel-spezifische Reduzierung der mutierten Polyglutamin-Proteine zur Behandlung der Huntington-Krankheit, spinozerebellären Ataxie Typ 3 und spinozerebellären Ataxie Typ 7 (Koordinator)
Ruhr-Universität Bochum
Humangenetik Bochum
ITÁLIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Ruolo della Struttura Coiled-Coil della proteina Huntingtin nella propagazione intracellulare degli aggregati PolyQ e nella progressione della malattia di Huntington
Institution: Information not provided - IT
ITÁLIE
EMILIA ROMAGNA
BOLOGNA
Enroll-HD - Registro prospettico in una coorte di pazienti HD - IT
Università di Bologna - Istituto di Clinica Neurologica
Laboratorio di Neurogenetica
ITÁLIE
LAZIO
ROMA
Alterazione del sistema corticale parvalbuminergico nel modello murino della malattia di Huntington: effetto farmacologico della fosfodiesterasi di tipo 4 (PDE4)
Fondazione EBRI
Istituto di Neurobiologia e Medicina Molecolare
ITÁLIE
LAZIO
ROMA
Analisi dell'apoptosi nelle patologie neurodegenerative attaverso mutagenesi di apaf1 (completato)
Università degli Studi di Roma Tor Vergata
Laboratorio di Genetica delle Popolazioni
ITÁLIE
LOMBARDIA
MILANO
Strategia terapeutica innovativa per trattare con colesterolo i neuroni nella malattia di Huntington: dagli studi preclinici alla preparazione di un trial clinico
Fondazione IRCCS Istituto Neurologico "Carlo Besta"
U.O.C. Genetica Medica e Neurogenetica
ITÁLIE
LOMBARDIA
MILANO
Targeting dei neuroni con il colesterolo. Come può cambiare il futuro delle persone con la malattia di Huntington
Università degli Studi di Milano - Scienze Biomolecolari e Biotecnologiche
Dipartimento di Bioscienze
NIZOZEMSKO
Zuid-Holland
LEIDEN
Investigating cell-specific pathology in Huntington's disease and spinocerebellar ataxia iPSC-derived brain assembloids before and after treatment with targeted antisense oligonucleotides
LUMC - Leids Universitair Medisch Centrum
PORTUGALSKO
CENTRO
COIMBRA
Análise das alterações da transcrição em modelos cerebrais e periféricos da doença de Huntington - influência da modulação das desacetilases das histonas.
Universidade de Coimbra - Centro de Neurociências e Biologia Celular
Grupo de Disfunção Mitocondrial e Morte Celular
ŠPANĚLSKO
Cataluña
BARCELONA
Desarrollo y validación de instrumentos específicos de evaluación cognitiva basados en la biologia de la enfermedad de Huntington
IIB Sant Pau - Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ŠPANĚLSKO
Cataluña
BARCELONA
Gliotransmisores y receptores de cannabinoides en el origen de los déficits cognitivos y de plasticidad sináptica en la enfermedad de Huntington
Universitat de Barcelona. Campus de Medicina - Clínic August Pi i Sunyer
Departamento de Biología Celular, Inmunología y Neurociencias
ŠPANĚLSKO
Comunidad Valenciana
VALENCIA
Modulación de la actividad de genes que controlan el metabolismo de las grasas como estrategia terapéutica en la enfermedad de Huntington
Hospital Universitario y Politécnico La Fe
Fundación para la Investigación del Hospital Universitari La Fe
ŠPANĚLSKO
Madrid
MADRID
Gliotransmisores y receptores de cannabinoides en el origen de los déficits cognitivos y de plasticidad sináptica en la enfermedad de Huntington
Instituto Cajal (CSIC)
Laboratorio de redes neuro-gliales
ŠPANĚLSKO
Madrid
MADRID
Gliotransmisores y receptores de cannabinoides en el origen de los déficits cognitivos y de plasticidad sináptica en la enfermedad de Huntington
Universidad Complutense de Madrid. Facultad de Medicina
Departamento de Bioquímica y Biología Molecular (Medicina)
ŠVÉDSKO
Region Skåne
LUND
BAGADILICO: Hypotalamiska forandringar och biomarkorer vid Huntingtons sjukdom
Lunds Universitet
Department of Experimental Medical Science
ŠVÉDSKO
Region Skåne
LUND
Inflammation vid Huntingtons sjukdom, betydelse för sjukdomsbild och biomarkörer
Lunds Universitet
Department of Experimental Medical Science
ŠVÉDSKO
Region Stockholm
SOLNA
The functional organisation of the brain
Karolinska Institutet
Department of Clinical Neuroscience (CNS)
ŠVÝCARSKO
Suisse Alémanique
ZÜRICH
Multinational research projects on Health and Social Care for Neurodegenerative Diseases DOMINO-HD (HESOCARE-329-017)
Universitätsspital Zürich
Klinik für Neurologie
ŠVÝCARSKO
Suisse Romande
LAUSANNE
Vers la réparation génique de la maladie de Huntington
Centre Hospitalier Universitaire Vaudois CHUV
Laboratoire des neurothérapies et neuromodulation
SPOJENÉ KRÁLOVSTVÍ
Avon
BRISTOL
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort - UK
Southmead Hospital
North Bristol NHS Trust
SPOJENÉ KRÁLOVSTVÍ
Gwent
CARDIFF
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort - UK
Cardiff School of Biosciences
SPOJENÉ STÁTY
Maryland
BETHESDA
Developing inhibitors for PIP4Kgamma for Huntington's disease
National Center for Advancing Translational Sciences (NCATS-NIH)
Chemistry Technologies
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Investigating cd47-sirpa as novel protective signals during cns synaptic pruning
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Nanocarriers designed to deliver nucleic acids to brain
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Epigenetic pathology and therapy in huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Extrinsic mechanisms governing injury-induced axon degeneration
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Identification of gpr52 antagonists as potential treatments for huntington disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Identification of small molecules that decrease the activity of the huntingtin gene promoter for the potential treatment of huntington disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Identification of small molecules that increase activity of the huntingtin antisense promoter for the potential treatment of huntington disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Quantitative systems pharmacology approach to identify cytoprotective agents and pathways for huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Using a disease-affected cell to synthesize its own drug
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Cortical pathophysiology in mouse models of huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Cortico-basal ganglia connectivity in a non-human primate model of huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Early detection of huntington's disease: longitudinal analysis of basal ganglia and cortical thickness
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Genetic correction of mutant huntingtin in vivo
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Huntington's disease: a novel developmental oligodendrogliopathy
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Identifying factors regulating medium spiny neuron differentiation or maintenance as therapeutic targets for huntington's disease using induced pluripotent stem cells
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Mechanism of dna strand-break repair deficiency in huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Mechanism of modulation of huntingtin exon 1 aggregation by profilin
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Rhes-sumo circuitry in huntington's disease pathogenesis
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Structure of triplet repeat mrna in neurodegenerative disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
The regulation of synaptic connectivity and homeostasis by huntingtin
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Crmp2; mitochondria; and huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Control of excitatory synapse formation by huntingtin
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Determinants of cell type-specific vulnerability in huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disorders
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Improved monitoring of premanifest and early huntingtons using 7t multimodal mri
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Mitochondrial fragmentation and neurodegeneration in huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Mscs engineered to produce brain-derived neurotrophic factor for the treatment of huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
N-terminal huntingtin and huntington disease neuropathology
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Phosphoinositide signaling: novel potential targets for huntington disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Rare variant whole genome analysis and ipsc validation of putative genetic modifiers of huntington disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Endogenous regulation of huntingtin expression as a therapeutic target for huntington's disease
Institution: Information not provided - US
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Validation of Novel Pathogenic Post-Translational Modifications of Huntingtin, and of Modifying Enzymes as Therapeutic Targets for Huntington's Disease
Institution: Information not provided - US
FINSKO
Finland
OULU
FINCA mouse as a tool to study mechanisms behind severe fibrosis and neurodegeneration
University of Oulu
Biocenter Oulu
ŠPANĚLSKO
Asturias
OVIEDO
El papel patogénico emergente de los alelos intermedios en el gen HTT: desde las evidencias neuropatológicas a las moleculares
Fundación para la Investigación Biosanitaria del Principado de Asturias
FINBA: Fundación para la Investigación Biosanitaria del Principado de Asturias
ŠPANĚLSKO
Cataluña
BARCELONA
Genómica avanzada y lipidómica para la identificación de nuevas causas genéticas de trastornos de movimiento hereditarios
Instituto de Química Avanzada de Cataluña
Unidad de Investigación en Moléculas Bioactivas
ŠPANĚLSKO
Cataluña
L'HOSPITALET DE LLOBREGAT
Genómica avanzada y lipidómica para la identificación de nuevas causas genéticas de trastornos de movimiento hereditarios
IDIBELL - Instituto de Investigación Biomédica de Bellvitge
Laboratorio de Enfermedades Neurometabólicas
ŠPANĚLSKO
País Vasco
SAN SEBASTIÁN
Genómica avanzada y lipidómica para la identificación de nuevas causas genéticas de trastornos de movimiento hereditarios
Instituto de Investigación Sanitaria Biodonostia
Área de Neurociencias
FRANCIE
ILE-DE-FRANCE
PARIS
La surexpression du gène de la neuroglobine : un outil prometteur pour traiter un large spectre de troubles neurologiques grâce à sa capacité à préserver de manière sûre et durable l'intégrité mitochondriale
Institut National de la Santé et de la Recherche Médicale
ITÁLIE
LAZIO
ROMA
Malattie rare causate dalla deregolazione funzionale delle proteine Rho GTPasi
ISS - Istituto Superiore di Sanità
Centro Nazionale Malattie Rare
ŠPANĚLSKO
Cataluña
BARCELONA
iGenCO: análisis genómico exhaustivo y análisis cross-ómico para enfermedades minoritarias no diagnosticadas en una plataforma colaborativa amigable
Centro de Regulación Genómica
Centro Nacional de Análisis Genómico
ŠPANĚLSKO
Cataluña
BARCELONA
iGenCO: análisis genómico exhaustivo y análisis cross-ómico para enfermedades minoritarias no diagnosticadas en una plataforma colaborativa amigable
ISGlobal - Instituto de Salud Global de Barcelona
Programa de investigación en Enfermedades no transmisibles y medio ambiente
KANADA
Colombie-Britannique
VICTORIA
Silent Genomes: Reducing health care disparities and improving diagnostic success for children with genetic diseases from Indigenous populations
University of Victoria
Community Genetics Research Program/Island Medical Program
KANADA
Ontario
TORONTO
Beyond the Genome: Transcriptome Based Diagnostics for Rare Diseases and Cancer
Hospital for Sick Children, Research Institute
FINSKO
Finland
OULU
Novel Diagnostics and Treatment Strategies for Developmental Disorders, Childhood Epilepsies and Movement Disorders
University of Oulu
Biocenter Oulu
ŠPANĚLSKO
Andalucía
SEVILLA
Desarrollo de herramientas bioinformáticas para el manejo automático de hallazgos secundarios y su uso en el asesoramiento genético y farmacogenético
Fundación Progreso y Salud
Área de bioinformática clínica
ŠPANĚLSKO
Cataluña
BARCELONA
Red interhospitalaria catalana de variantes genéticas para mejorar el diagnóstico genético en enfermedades raras
Centro de Regulación Genómica
Archivo europeo de genomas y fenomas del CRG
ŠPANĚLSKO
Cataluña
BARCELONA
Red interhospitalaria catalana de variantes genéticas para mejorar el diagnóstico genético en enfermedades raras
Hospital Clínic de Barcelona
Servicio de Inmunologia
ŠPANĚLSKO
Cataluña
BARCELONA
Red interhospitalaria catalana de variantes genéticas para mejorar el diagnóstico genético en enfermedades raras
Hospital Universitari Vall d'Hebron
Laboratorio de Genética
ŠPANĚLSKO
Cataluña
BARCELONA
Red interhospitalaria catalana de variantes genéticas para mejorar el diagnóstico genético en enfermedades raras
Hospital de la Santa Creu i Sant Pau
Servicio de Genética
ŠPANĚLSKO
Cataluña
ESPLUGUES DE LLOBREGAT
Red federada de genómica funcional de enfermedades no diagnosticadas y enfermedades raras, RareFunction
Fundació Sant Joan de Déu - Institut de Recerca Sant Joan de Déu
Grupo de investigación en Neurogenética y Medicina Molecular
ŠPANĚLSKO
Cataluña
ESPLUGUES DE LLOBREGAT
Red interhospitalaria catalana de variantes genéticas para mejorar el diagnóstico genético en enfermedades raras
Hospital Sant Joan de Déu Barcelona
Servicio de Laboratorio
ŠPANĚLSKO
Cataluña
L'HOSPITALET DE LLOBREGAT
Red interhospitalaria catalana de variantes genéticas para mejorar el diagnóstico genético en enfermedades raras
Hospital Universitari de Bellvitge
Unidad de Genética Molecular
ŠPANĚLSKO
Comunidad Valenciana
VALENCIA
Estudios clínicos, bases genéticas y biomarcadores pronóstico en enfermedades raras neurodegenerativas
Centro de Investigación Príncipe Felipe (CIPF)
CIPF: Centro de Investigación Príncipe Felipe
ŠPANĚLSKO
Madrid
MADRID
Identificación de nuevos genes causantes de enfermedades raras en pacientes pediátricos, identificación de dianas farmacológicas, y descubrimiento de fármacos, los pasos para una medicina personalizada
Instituto de Investigación Hospital 12 de Octubre
Grupo de investigación en enfermedades raras, mitocondriales y neuromusculares
Multicentrické výzkumné projekty
- Centre de Recherche en Cancérologie de Marseille
- Télomères et Chromatine
- Parc scientifique et technologiques de Luminy
- Trophos SA
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Institut für Medizinische Genetik und angewandte Genomik Tübingen
- Institut für Medizinische Genetik und angewandte Genomik
- Universitäts- und Rehabilitationskliniken Ulm (RKU)
- Zentrale Koordination des Europäischen HD Netzwerks
- Zentrum für Seltene Erkrankungen am Universitätsklinikum Ulm
- Zentrum für Seltene Erkrankungen (ZSE) ULM
- Ruhr-Universität Bochum
- Humangenetik Bochum
- Università degli Studi di Milano - Scienze Farmacologiche e Biomolecolari
- Laboratorio di Biologia delle Cellule Staminali
- SIENA BIOTECH SPA
- SIENA BIOTECH SPA
- Unità di Neurobiologia
- John van Geest Centre for Brain Repair
- NeuroNE
- Cardiff School of Biosciences
- Alzheimer Europe Office
- Max-Planck-Institut für Multidisziplinäre Naturwissenschaften
- Abteilung Molekulare Neurobiologie
- Azienda Ospedaliera di Padova
- Clinica Pediatrica
FRANCIE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
REPETOMICS: Genomic Instability of Expanded Repeats in HD and ALS/FTD
FRANCIE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
MITOTARGET: dysfonction mitochondriale dans les maladies neurodégénératives: vers de nouvelles thérapies
NĚMECKO
Baden-Württemberg
TÜBINGEN
RATSTREAM: European project on the characterisation of transgenic rat models for neurodegenerative and psychiatric diseases: Automated home cage analyses, live imaging and treatment (FINISHED)
NĚMECKO
Baden-Württemberg
TÜBINGEN
NEUROMODEL: Akademisch-industrielles Austausch- und Trainings-Netzwerk zur Erforschung neuer Therapieansätze für die Behandlung von Morbus Huntington
NĚMECKO
Baden-Württemberg
TÜBINGEN
TreatPolyQ: Industrial Academic Initial Training Network (Itn) Towards Treatment Of Polyglutamine Diseases -terminated-
NĚMECKO
Baden-Württemberg
TÜBINGEN
PhenoRat: European Industrial Doctorate on the generation, characterisation and validation of transgenic rat models of two neurodegenerative diseases: Huntington's disease and spinocerebellar ataxia type 17
NĚMECKO
Baden-Württemberg
TÜBINGEN
Neuromics: Integrated European -omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases
NĚMECKO
Baden-Württemberg
ULM
EHDN: Europäisches Huntington Netzwerk
NĚMECKO
Baden-Württemberg
ULM
Enroll-HD: Eine prospektive Registrierungsstudie in einer globalen Huntington-Kohorte
NĚMECKO
Nordrhein-Westfalen
BOCHUM
TreatPolyQ: Allel-spezifische Reduzierung der mutierten Polyglutamin-Proteine zur Behandlung der Huntington-Krankheit, spinozerebellären Ataxie Typ 3 und spinozerebellären Ataxie Typ 7
ITÁLIE
LOMBARDIA
MILANO
NEuroStemCell: Consorzio europeo per la terapia con cellule staminali nelle malattie neurodegenerative
ITÁLIE
TOSCANA
SIENA
PADDINGTON: pharmacodynamic approaches to demonstration of disease-modification in Huntington's disease by SEN0014196 (TERMINATED)
ITÁLIE
TOSCANA
SIENA
TAMAHUD: identification of early disease markers, novel pharmacologically tractable targets and small molecule phenotypic modulators in Huntington's Disease
SPOJENÉ KRÁLOVSTVÍ
Cambridgeshire
CAMBRIDGE
EUNEURONE: European Consortium for Research in Neurodegenerative Diseases
SPOJENÉ KRÁLOVSTVÍ
Gwent
CARDIFF
REPAIR-HD: Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington's disease
LUCEMBURSKO
LUXEMBOURG
LUXEMBOURG
Alzheimer Europe: base de données européenne sur les formes rares de démence
NĚMECKO
Niedersachsen
GÖTTINGEN
EUROSPIN: European consortium on synaptic protein networks in Neurological and Psychiatric diseases
ITÁLIE
VENETO
PADOVA